Advanced in Richter Syndrome

Dr. Meagan A. Jacoby

Oncology
Washington University
1 Barnes Jewish Hospital Plz, 
Saint Louis, MO 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Advanced in Richter Syndrome
Washington University
1 Barnes Jewish Hospital Plz, 
Saint Louis, MO 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Meagan Jacoby is an Oncologist in Saint Louis, Missouri. Dr. Jacoby is rated as an Advanced provider by MediFind in the treatment of Richter Syndrome. Her top areas of expertise are Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Bone Marrow Aspiration, and Colonoscopy. Dr. Jacoby is currently accepting new patients.

Her clinical research consists of co-authoring 55 peer reviewed articles and participating in 21 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Licenses
Internal Medicine in MO
Hospital Affiliations
Barnes-Jewish St Peters Hospital
Barnes Jewish Hospital
Christian Hospital Northeast
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Cox Health
  • EPO
  • PPO
Essence Healthcare
  • INSURANCE PLAN
  • MEDICARE MAPD
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Home State Health
  • EPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

WASHINGTON UNIVERSITY
1 Barnes Jewish Hospital Plz, Saint Louis, MO 63110

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

21 Clinical Trials

Analysis of Dendritic Cells in Patients With Acute or Chronic Skin Graft Versus Host Disease
Analysis of Dendritic Cells in Patients With Acute or Chronic Skin Graft Versus Host Disease
Enrollment Status: Recruiting
Publish Date: March 13, 2025
Intervention Type: Procedure
Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant in Children and Adults
Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant in Children and Adults
Enrollment Status: Completed
Publish Date: October 14, 2025
Intervention Type: Procedure, Drug
Study Drug: CIML NK Cell Infusion
Study Phase: Phase 1/Phase 2
A Phase Ib Study of AZD6738 for Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia Progressing on Front-Line Therapy
A Phase Ib Study of AZD6738 for Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia Progressing on Front-Line Therapy
Enrollment Status: Active_not_recruiting
Publish Date: September 29, 2025
Intervention Type: Drug
Study Drug: AZD6738
Study Phase: Phase 1
A Phase II Study of Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation
A Phase II Study of Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation
Enrollment Status: Active_not_recruiting
Publish Date: September 23, 2025
Intervention Type: Procedure, Drug
Study Drugs: Tacrolimus, Mycophenolate mofetil, G-CSF, ALT-803
Study Phase: Phase 2
Phase II Trial With Safety Lead in of Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell Lymphomas
Phase II Trial With Safety Lead in of Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell Lymphomas
Enrollment Status: Active_not_recruiting
Publish Date: May 25, 2025
Intervention Type: Drug, Procedure
Study Drug: Duvelisib
Study Phase: Phase 2
A Pilot Study of CPX-351 (Vyxeos™) for Transplant Eligible, Higher Risk Patients With Myelodysplastic Syndrome
A Pilot Study of CPX-351 (Vyxeos™) for Transplant Eligible, Higher Risk Patients With Myelodysplastic Syndrome
Enrollment Status: Active_not_recruiting
Publish Date: April 09, 2025
Intervention Type: Procedure, Drug
Study Drugs: Daunorubicin, Cytarabine
Study Phase: Phase 1
A Single-Arm, Open-Label, Pilot Study and Expansion Study of JAK Inhibitor Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
A Single-Arm, Open-Label, Pilot Study and Expansion Study of JAK Inhibitor Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
Enrollment Status: Completed
Publish Date: April 06, 2025
Intervention Type: Drug, Other, Procedure
Study Drug: Itacitinib
Study Phase: Phase 1
Identification of AML/MDS Drug Sensitization by in Vivo Chemotherapy Administration
Identification of AML/MDS Drug Sensitization by in Vivo Chemotherapy Administration
Enrollment Status: Active_not_recruiting
Publish Date: February 27, 2025
Intervention Type: Procedure
Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance
Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance
Enrollment Status: Active_not_recruiting
Publish Date: October 28, 2024
Intervention Type: Procedure, Drug, Device
Study Phase: Phase 2
A Phase 1/2 Study of Cytokine-Induced Memory-Like NK Cells in Patients With AML or MDS
A Phase 1/2 Study of Cytokine-Induced Memory-Like NK Cells in Patients With AML or MDS
Enrollment Status: Terminated
Publish Date: January 17, 2024
Intervention Type: Procedure, Biological, Drug
Study Drugs: Fludarabine, Cyclophosphamide, ALT-803, Cytokine-Induced Natural Killer T Cells, IL-2
Study Phase: Phase 1/Phase 2
A Phase I Study of ApoGraft for the Prevention of Acute Graft Versus Host Disease in Haploidentical Hematopoietic Cell Transplant Recipients
A Phase I Study of ApoGraft for the Prevention of Acute Graft Versus Host Disease in Haploidentical Hematopoietic Cell Transplant Recipients
Enrollment Status: Terminated
Publish Date: May 19, 2023
Intervention Type: Drug
Study Drug: ApoGraft
Study Phase: Phase 1
A Single-Arm, Open-Label Phase I Clinical Trial of a JAK Inhibitor, Baricitinib, for the Prophylaxis of Graft-Versus-Host Disease After Peripheral Blood Hematopoietic Cell Transplantation
A Single-Arm, Open-Label Phase I Clinical Trial of a JAK Inhibitor, Baricitinib, for the Prophylaxis of Graft-Versus-Host Disease After Peripheral Blood Hematopoietic Cell Transplantation
Enrollment Status: Completed
Publish Date: May 10, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 1
A Phase 2 Study of Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed AML
A Phase 2 Study of Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed AML
Enrollment Status: Withdrawn
Publish Date: April 04, 2023
Intervention Type: Procedure, Drug, Biological
Study Drugs: Cytokine induced memory-like NK cells, Fludarabine, Ara-C, G-CSF, Interleukin-2
Study Phase: Phase 2
A Phase 2 Study of Cytokine-induced Memory-like NK Cells in Relapsed/Refractory AML and MDS
A Phase 2 Study of Cytokine-induced Memory-like NK Cells in Relapsed/Refractory AML and MDS
Enrollment Status: Withdrawn
Publish Date: March 11, 2022
Intervention Type: Procedure, Drug, Biological
Study Phase: Phase 2
A Phase 1, Multicenter, Open Label Study of AMV564, a Bispecific CD33/CD3 T-cell Engager, in Patients With Intermediate or High-Risk Myelodysplastic Syndromes
A Phase 1, Multicenter, Open Label Study of AMV564, a Bispecific CD33/CD3 T-cell Engager, in Patients With Intermediate or High-Risk Myelodysplastic Syndromes
Enrollment Status: Completed
Publish Date: October 12, 2021
Intervention Type: Drug
Study Drug: AMV564 Bispecific CD33/CD3 T Cell Engager
Study Phase: Phase 1
A Phase I/II Study of Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation
A Phase I/II Study of Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation
Enrollment Status: Terminated
Publish Date: October 20, 2020
Intervention Type: Radiation, Drug, Procedure
Study Phase: Phase 1
An Investigator Sponsored Phase I/II Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia
An Investigator Sponsored Phase I/II Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia
Enrollment Status: Completed
Publish Date: March 13, 2020
Intervention Type: Procedure, Drug
Study Phase: Phase 1/Phase 2
A Pilot Study of CX-01 Combined With Azacitidine in the Treatment of Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia
A Pilot Study of CX-01 Combined With Azacitidine in the Treatment of Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia
Enrollment Status: Completed
Publish Date: December 05, 2019
Intervention Type: Procedure, Drug
Study Phase: Phase 1
A Study of Granix to Disrupt the Bone Marrow Microenvironment in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation
A Study of Granix to Disrupt the Bone Marrow Microenvironment in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation
Enrollment Status: Terminated
Publish Date: November 26, 2019
Intervention Type: Procedure, Drug
Study Phase: Phase 2
Phase I/II Trial of Intravenous Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation
Phase I/II Trial of Intravenous Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation
Enrollment Status: Terminated
Publish Date: October 16, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Pilot Study of Myeloablative Allogeneic or Haploidentical Stem Cell Transplantation With High Dose PT-Cy in Relapsed/Refractory AML
A Pilot Study of Myeloablative Allogeneic or Haploidentical Stem Cell Transplantation With High Dose PT-Cy in Relapsed/Refractory AML
Enrollment Status: Terminated
Publish Date: October 12, 2018
Intervention Type: Radiation, Drug, Procedure
Study Phase: Phase 1
View 20 Less Clinical Trials

54 Total Publications

NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 2.2025.
NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 2.2025.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: March 12, 2025
Similar Doctors
Distinguished in Richter Syndrome
Dr. Brad S. Kahl
Oncology
Distinguished in Richter Syndrome
Dr. Brad S. Kahl
Oncology

Washington University

5201 Mid America Plz, 
Saint Louis, MO 
 (40.8 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Brad Kahl is an Oncologist in Saint Louis, Missouri. Dr. Kahl is rated as an Elite provider by MediFind in the treatment of Richter Syndrome. His top areas of expertise are Mantle Cell Lymphoma (MCL), Follicular Lymphoma, Non-Hodgkin Lymphoma, Bone Marrow Aspiration, and Splenectomy. Dr. Kahl is currently accepting new patients.

Distinguished in Richter Syndrome
Dr. Camille N. Abboud
Oncology
Distinguished in Richter Syndrome
Dr. Camille N. Abboud
Oncology

Washington University Physicians In Illinois, Inc

1418 Cross St, Suite 180, 
Shiloh, IL 
 (20.0 miles away)
618-607-1340
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Camille Abboud is an Oncologist in Shiloh, Illinois. Dr. Abboud is rated as an Elite provider by MediFind in the treatment of Richter Syndrome. His top areas of expertise are Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelogenous Leukemia (CML), Leukemia, and Bone Marrow Aspiration. Dr. Abboud is currently accepting new patients.

Distinguished in Richter Syndrome
Dr. John L. Visconti
Oncology | Hematology
Distinguished in Richter Syndrome
Dr. John L. Visconti
Oncology | Hematology

Washington University

5201 Mid America Plz, 
Saint Louis, MO 
 (40.8 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

John Visconti is an Oncologist and a Hematologist in Saint Louis, Missouri. Dr. Visconti is rated as a Distinguished provider by MediFind in the treatment of Richter Syndrome. His top areas of expertise are Pleuropulmonary Blastoma, Lung Cancer, Paget Disease of the Breast, and Familial Colorectal Cancer. Dr. Visconti is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Jacoby's expertise for a condition
ConditionClose
View All 14 Advanced Conditions
View All 20 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile